| Identification | Back Directory | [Name]
Derazantinib | [CAS]
1234356-69-4 | [Synonyms]
ARQ-087
CPD1093
CS-2677
Derazantinib
Derazantinib (ARQ-087)
ARQ-087;ARQ087;ARQ 087;CPD1093
ARQ-087;ARQ087;DERAZANTINIB;ARQ 087
(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine
(6R)-6-(2-fluorophenyl)-5,6-dihydro-N-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-Benzo[h]quinazolin-2-amine
Benzo[h]quinazolin-2-amine, 6-(2-fluorophenyl)-5,6-dihydro-N-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-, (6R)- | [Molecular Formula]
C29H29FN4O | [MDL Number]
MFCD30532770 | [MOL File]
1234356-69-4.mol | [Molecular Weight]
468.57 |
| Chemical Properties | Back Directory | [Boiling point ]
615.1±65.0 °C(Predicted) | [density ]
1.218±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:47.67(Max Conc. mg/mL);101.73(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);64.02(Max Conc. mM)
DMF:PBS (pH 7.2) (1:3):0.25(Max Conc. mg/mL);0.53(Max Conc. mM) | [form ]
A crystalline solid | [pka]
9.04±0.19(Predicted) |
| Hazard Information | Back Directory | [Uses]
Derazantinib is an intermediate in the preparation of imidazopyridinyl compounds for treating proliferative disorders like cancer, Proteus syndrome and others. |
|
|